Search clinical trials for: Moderate to Severe Rheumatoid Arthritis

Total 477058 results

ImmuneMed, Inc.

Not yet recruiting

A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Moderate to Severe Rheumatoid Arthritis

Netherlands
Amgen

Recruiting

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Sjögren's Syndrome (SS)

United States, Japan
Amgen

Recruiting

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Sjogren's Syndrome

United States, Argentina, Japan
IGM Biosciences, Inc.

Recruiting

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Arthritis | Arthritis, Rheumatoid | Rheumatoid Arthritis

United States, Poland
AnaptysBio, Inc.

Recruiting

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)

Rheumatoid Arthritis

United States, Argentina, Estonia, Georgia, Hungary, Mexico, Moldova, Republic of, Peru, Poland, Slovakia, Belgium, Canada, Germany, Italy, Spain
AbbVie

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)

Rheumatoid Arthritis

United States, Japan, United Kingdom, Canada, Korea, Republic of, Puerto Rico, South Africa, Hungary, Bulgaria, Spain, Portugal, Chile, Croatia, France, Belgium, Germany, Greece, Romania, Brazil, Italy, Serbia, China, Colombia, Mexico
Pfizer

Recruiting

Korean Post-marketing Surveillance for Xeljanz XR (XRPMS)

Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Active Moderate to Severe Rheumatoid Arthritis

Korea, Republic of
AbbVie

Recruiting

A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

Rheumatoid Arthritis (RA) | Ankylosing Spondylitis (AS) | Atopic Dermatitis (AD) | Psoriatic Arthritis (PsA)

Korea, Republic of
Kiniksa Pharmaceuticals, Ltd.

Completed

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Arthritis, Rheumatoid

United States, Poland, Hungary, Georgia, Czechia, South Africa, Bulgaria
Navidea Biopharmaceuticals

Active, not recruiting

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Rheumatoid Arthritis

United States
AbbVie

Completed

A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis (UPHOLD)

Rheumatoid Arthritis (RA)

Argentina, Australia, Austria, Belgium, France, Germany, Greece, Ireland, Israel, Italy, Kuwait, Mexico, Russian Federation, Saudi Arabia, Spain, Switzerland, Taiwan, United Arab Emirates, Uruguay
Eli Lilly and Company

Active, not recruiting

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)

Immune System Diseases | Autoimmune Diseases | Arthritis | Joint Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Connective Tissue Diseases | Rheumatoid Arthritis

United States, Spain, China, Mexico, Puerto Rico, Japan, Canada, Argentina, Poland, Hungary, Greece
AbbVie

Completed

An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice (UPDATE)

Rheumatoid Arthritis

Hungary
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (contRAst 1)

Arthritis, Rheumatoid

Hungary, Poland, Malaysia, Spain, China, Russian Federation, India, United Kingdom, Italy, Serbia
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

China
SetPoint Medical Corporation

Active, not recruiting

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis (RESET-RA)

Rheumatoid Arthritis

United States
Hoffmann-La Roche

Completed

An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation
GlaxoSmithKline
Iqvia Pty Ltd

Terminated

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (contRAst 2)

Arthritis, Rheumatoid

United States, Australia, Germany, Japan, Korea, Republic of, Poland, Bulgaria, Estonia, Hungary, Mexico, Russian Federation, Spain, Thailand, Colombia, China, Argentina, United Kingdom, France
Hoffmann-La Roche

Completed

An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy

Rheumatoid Arthritis

China
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Completed

Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Bangladesh
Aclaris Therapeutics, Inc.

Completed

ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA

Rheumatoid Arthritis

United States, Bulgaria, Czechia, Poland
Lynk Pharmaceuticals Co., Ltd

Completed

A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
R-Pharm International, LLC
IQVIA Pvt. Ltd; OCT Clinical Trials

Completed

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis (CREDO 4)

Rheumatoid Arthritis

Korea, Republic of, United States, Germany, Hungary, Bulgaria, Poland, Taiwan, Mexico, Czechia, Argentina, United Kingdom, Belarus, Brazil, Colombia, Estonia, Latvia, Lithuania, Russian Federation
R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials; Mene Research

Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (CREDO 3)

Rheumatoid Arthritis

United States, Korea, Republic of, Germany, Czechia, Mexico, Hungary, Poland, Argentina, Brazil, Colombia, Russian Federation
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis

Moderate to Severe Active Rheumatoid Arthritis

China
R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials

Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 2)

Rheumatoid Arthritis

United States, Germany, Korea, Republic of, Bulgaria, Poland, Taiwan, Mexico, Hungary, Czechia, United Kingdom, Lithuania, Argentina, Brazil, Colombia, Estonia, Latvia, Russian Federation, Romania
R-Pharm International, LLC
Quintiles, Inc.; OCT Clinical Trials; Mene Research

Completed

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 1)

Rheumatoid Arthritis

Belarus, Bulgaria, Russian Federation
RemeGen Co., Ltd.

Completed

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Moderate and Severe RheumatoId Arthritis

China
Pfizer

Completed

Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis (ESCALATE-RA)

Arthritis, Rheumatoid

Germany
AbbVie

Terminated

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Australia, Canada, Czechia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, Taiwan, Turkey, Ukraine
Xiaoming Gong

Completed

Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)

Arthritis, Rheumatoid

United States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
AbbVie

Active, not recruiting

A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis (CLOSEUP)

Rheumatoid Arthritis (RA)

Canada
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary, Serbia, Georgia, Russian Federation, Slovakia, Czechia, Bulgaria, Moldova, Republic of, Poland
Aclaris Therapeutics, Inc.

Completed

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Rheumatoid Arthritis

United States
Abivax S.A.

Completed

Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Belgium, France, Czechia, Hungary, Poland
Novartis Pharmaceuticals

Terminated

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)

Sjögren Syndrome

Spain, United States, Belgium, Hungary, Germany, Switzerland, Australia, Denmark, China, Taiwan, United Kingdom, Bulgaria
Abivax S.A.

Completed

Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Belgium, France, Czechia, Hungary, Poland
R-Pharm International, LLC
IQVIA RDS Ireland Ltd; Thermo Fisher Scientific FS

Completed

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Rheumatoid Arthritis

Bulgaria, Moldova, Republic of
Kang Stem Biotech Co., Ltd.

Completed

Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Korea, Republic of
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (LADYBUG)

Rheumatoid Arthritis

Ukraine, Georgia, Bulgaria, Poland
Shanghai Henlius Biotech

Completed

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

Rheumatoid Arthritis
Shanghai Henlius Biotech

Completed

Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis

Moderately to Severely Active Rheumatoid Arthritis

China
Eli Lilly and Company

Completed

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis (RA-BEYOND)

Rheumatoid Arthritis

United States, Canada, Puerto Rico, China, Spain, Australia, Japan, India, Portugal, Germany, Turkey, Switzerland, Mexico, Poland, Belgium, France, Hungary, Korea, Republic of, Russian Federation, Taiwan, Israel, Austria, Italy, Argen... and more
AbbVie

Withdrawn

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

Sjogren's Syndrome (SS)

Netherlands
AbbVie

Completed

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

Rheumatoid Arthritis (RA)

Brazil, China, Korea, Republic of
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Germany, Hungary, Israel, Netherlands, Poland, Puerto Rico
GlaxoSmithKline

Completed

Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

Spain, Germany, Russian Federation, United Kingdom, Italy, Poland
Gilead Sciences
Galapagos NV

Completed

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (FINCH 1)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Israel, Bulgaria, India, Serbia, South Africa, Korea, Republic of, Japan, Russian Federation, Argentina, Germany, New Zealand, Thailand, Hungary, Netherlands, Slovaki... and more
Gilead Sciences
Galapagos NV

Completed

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy (FINCH 3)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Korea, Republic of, Japan, Australia, Chile, Russian Federation, Argentina, Germany, New Zealand, Th... and more

3

Subscribe